To the Editor, We read with interest the recent paper by Bardai et al, 1 which reports that epilepsy and antiepileptic drugs (AEDs) were independently associated with sudden cardiac death (SCD). We are unconvinced that such a clear distinction between disease and drug effects can be made in this study as all people with epilepsy were by definition taking AEDs. We believe this is why SCD risk in those with epilepsy (table 2) and in AED users with epilepsy (table 3) was the same: OR 2.8 (95% CI 1.4 to 5.3). It is unclear whether these numbers reflect disease effects, drug effects or both.
It is reported that people with epilepsy are at increased risk of SCD, yet in this population there is a major diagnostic alternative: sudden unexpected death in epilepsy, an autopsy-negative mostly seizure-related type of sudden death with cardiac and noncardiac causes. 2 We do not believe that sudden death in people with epilepsy can be assumed to be of cardiac origin (vs, for example neurogenic respiratory depression) without documentation of a cardiac mechanism of death (eg, by ECG).
Carbamazepine and gabapentin were the only individual AEDs associated with increased SCD risk. The authors attribute this to the supposed sodium channel blocking properties of these drugs, but we believe that indication bias cannot be excluded. Carbamazepine is the drug of choice in people with focal seizures and stroke is a leading cause of this type of epilepsy, particularly in the elderly. 3 An important indication for gabapentin is diabetic chronic neuropathic pain. 4 It is possible that a worse cardiovascular status rather than sodium channel blocking properties explains the higher SCD risk in users of these AEDs.
Despite the use of a large database, many numbers are small, so the demonstrated significant effect for sodium channel blocking AEDs but not for nonsodium channel blocking AEDs may reflect limited sample size rather than differences in effect. There was a consistent trend; all reported AED ORs were greater than the null value.
This paper is important in that it confirms that epilepsy in the community is associated with an increased risk of sudden natural death. Future studies with additional documentation of death mechanisms, correction for indication bias and larger sample size are needed to explain the cause of this excess risk and clarify the role of AEDs.
Survival by stroke volume index in low-gradient normal EF severe aortic stenosis: insights into myocardial systolic dysfunction
To the Editor, We read with interest the recent article on survival by stroke volume index (SVI) in patients with low-gradient normal EF severe aortic stenosis, which demonstrated lower SVI is incrementally associated with mortality. 1 The authors discuss a putative mechanism of low stroke volume (SV) secondary to concentric remodelling which results in reduced LV cavity size. This impedes LV diastolic filling culminating in diminished systolic function despite normal EF. The authors quote evidence of systolic impairment, for example reduced longitudinal strain, in similar cohorts with preserved EF. 2 In the current study, the subgroup with lowest SVI, and therefore presumed most severe systolic impairment despite EF >50%, demonstrated the thickest relative wall measurements. We believe this observation helps to explain the apparent paradox between significant myocardial dysfunction and preservation of EF in this cohort and in the wider 'heart failure with preserved ejection fraction' context. Recent mathematical modelling of LV contraction has shown that both myocardial shortening and end-diastolic wall thickness are determinants of EF. 3 Essentially, absolute LV wall thickening, as defined by the absolute difference between wall thickness at end-systole and enddiastole, may be nearly normal in patients with concentric LV hypertrophy (LVH) because absolute systolic thickening will be augmented in response to increased enddiastolic LV wall thickness. As a result, the endocardial displacement and EF will also be normal, as the external LV volume remains fairly constant throughout the cardiac cycle 4 and the absolute wall thickening may appear to compensate for any contractile strain abnormality. The development of concentric LVH may be viewed as a compensatory response that normalises contractile stress and total contractile force. However, if contractile stress remains reduced, the contractile force will be inadequate and result in a fall in stroke volume despite the preserved EF. In order to understand the apparent discrepancy in SV and EF, one must distinguish between contractile strain and stress and the relationship between end-diastolic wall thickness and EF.
The authors elected to investigate SV indexed to body surface area. However, it would be interesting to know whether correcting EF for the presence of concentric LVH (EFc), as described in mathematical modelling studies of the LV, 3 would be a useful prognostic marker in this cohort of patients. After all, EFc is potentially an even more relevant allometric indexed value given the importance of end-diastolic wall thickness in patients with concentric LVH and systolic impairment but preserved EF.
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